Browse drugs

…minantly stereotactic radiosurgery (SRS)) followed by continued osimertinib, with encouraging PFS/OS and acceptable toxicity. By contrast, …

…state health sector in which several novel cancer drugs such as osimertinib, alectinib and immunotherapy are not approved for use in advanc…

…ring may help identify patients who could benefit from extended osimertinib therapy, although further clinical validation is warranted.ctDN…

…age in terms of PFS, it has a high incremental cost compared to afatinib. Therefore, the treatment is not cost-effective based on the th…

…Objectives There have been cases of cardiotoxicity induced by osimertinib in patients with non-small-cell lung cancer (NSCLC). However, l…

…cell lymphoma-2 (BCL-2)/BCL-extra-large (BCL-xL) inhibitor, and osimertinib in patients with EGFR-mutated advanced NSCLC.Methods Enrolled p…

… with identical EGFR mutations. This study investigates whether osimertinib, a third-generation EGFR-TKI, activates the nucleotide-binding …

…s of cardiac adverse events. Among third generation inhibitors, osimertinib (2.53, 1.53 to 4.19; high certainty; 8.9%) and lazertinib (2.84…

…s of disease, with contemporary randomised data emerging in the osimertinib era and ongoing trials addressing optimal timing and completene…

…), atezolizumab (Tecentriq), osimertinib (Tagrisso), ceritinib (Zykadia) and nintedanib (Vargatef). EMA labels for all products include…

…-rearranged metastatic NSCLC, median PFS reached 66 months with brigatinib, followed by brigatinib plus LCT (radiation and/or surgery), co…

…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …